What is Neuraxis's market cap?

Neuraxis (NRXS) has a market capitalization of $71.6M and trades on AMEX.

Who are Neuraxis's competitors?

Neuraxis's key competitors include electroCore, Inc., Ironwood Pharmaceuticals, Inc., Salix Pharmaceuticals, and others. These companies compete in similar markets and product categories.

Who does Neuraxis partner with?

Neuraxis's notable partners include Masimo Corporation, TKBMN, LLC.

Where is Neuraxis headquartered?

Neuraxis is headquartered in United States of America and employs approximately 19 people. It has been publicly traded since 2023.

Neuraxis (NRXS) Stock Fundamentals & Financials

Neuraxis, Inc. is a growth-stage medical technology company that develops and commercializes proprietary neuromodulation therapies for chronic gastrointestinal disorders.

Market cap

$71.58M+183%

Earnings

Q2 2026 report

August 11, 2026

Revenue$1.9MMiss by $71.3K EPS-$0.19Beat by $0.13

Read the full report

Next report

Nov 17, 2026 (in 2 months)

Revenue estimate$2.1M

EPS estimate-$0.21

Competitors

By market cap

AbbVie$464.82B+21.7%

LivaNova$4.4B+46.0%

Bausch Health Companies$2.1B-15.4%

Ironwood Pharmaceuticals$670.9M+218%

Neuropace, Inc.$489.1M+50.9%

electroCore, Inc.$90.6M+147%

Neuraxis$71.6M+198%

Nexalin Technology, Inc.$4.0M-72.5%

By revenue growth

electroCore, Inc.+33.5%

Ironwood Pharmaceuticals+26.2%

Neuropace, Inc.+16.9%

LivaNova+12.4%

AbbVie+10.4%

Bausch Health Companies+8.2%

By net margin

Ironwood Pharmaceuticals33.36%+35.9pp

AbbVie9.8%+3.3pp

Bausch Health Companies-1.88%-9.1pp

LivaNova-16.12%+29.5pp

Neuropace, Inc.-19.34%+11.3pp

electroCore, Inc.-39.96%+7.9pp

Profile

Neuraxis, Inc. is a growth-stage medical technology company that develops and commercializes proprietary neuromodulation therapies for chronic gastrointestinal disorders. The company's core value proposition centers on its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which provides a drug-free alternative for treating disorders of the gut-brain interaction in both pediatric and adult populations.

Competitive position

Neuraxis holds a first-to-market advantage with the only FDA-cleared PENFS treatment recommended by major pediatric academic society guidelines.

GeographiesUnited States

Customer segmentsPediatric healthcare providers, Gastroenterology clinics, Government healthcare systems

Business modelDirect-to-hospital sales, Medical device manufacturing

SuppliersContract manufacturing services in Indiana and Michigan, Specialized medical component suppliers, Electronic pulse generator manufacturers

CustomersChildren's hospitals, Veterans Affairs (VA) hospitals, Gastroenterology specialty clinics

CountryUnited States of America

Listed2023

Employees19.0

CEOBrian Carrico

SectorHealthcare

IndustryBiotechnology

Websiteneuraxis.com

FilingsSEC EDGAR

FAQ

What is Neuraxis's market cap?: Neuraxis (NRXS) has a market capitalization of $71.6M and trades on AMEX.
Who are Neuraxis's competitors?: Neuraxis's key competitors include electroCore, Inc., Ironwood Pharmaceuticals, Inc., Salix Pharmaceuticals, and others. These companies compete in similar markets and product categories.
Who does Neuraxis partner with?: Neuraxis's notable partners include Masimo Corporation, TKBMN, LLC.
Where is Neuraxis headquartered?: Neuraxis is headquartered in United States of America and employs approximately 19 people. It has been publicly traded since 2023.